Accueil   Diary - News   All news Imaxio sells Trolovol®

Imaxio sells Trolovol®

Imaxio sells Trolovol® (D-penicillamine) to focus on vaccines


This divestment enables Imaxio to focus exclusively on the development of its pipeline of vaccine candidates based on the IMX313 technology, and on the commercialisation of the vaccine Spirolept®


Read the press release




By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to More details are available by clicking here I agree